



Bal Pharma Limited

29.06.2021

The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

BSE Limited
Mumbai.

Dear Sir,

Sub : Outcome of the Board Meeting.

The Board of Directors of the Company has met today and *inter alia* transacted the following business.

1.Approved the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2021. A copy of the Audited financials (Standalone and Consolidated) along with audit report's are enclosed with this letter for submission to the exchanges.

2.Recommended dividend of Re.1/- per equity share of Rs.10/- each, payable subject to the approval of members at the ensuing Annual General Meeting of the Company.

3. Decided to convene the 34th Annual General Meeting of the Company on Friday 24th September, 2021, by audio visual means.

4. Decided to close the Register of Members and Share Transfer books of the Company from 18th September 2021 to 24th September 2021 (Both days inclusive).

5. The Board considered and authorised Mr. Shailesh Siroya, Managing Director to undertake restructuring process of the group Companies, subject to various legal and taxation aspects.

The meeting commenced at 4.00 p.m and concluded at 5.30 p.m on 29.06.2021.

Please take this intimation on record.

For Bal Pharma Limited


Shailesh Siroya
Managing Director



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India
Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. : 41570813 / 19 Fax : 41570820